Technical Field
The present invention relates to condensed purine
derivatives exhibiting adenosine A3 receptor antagonizing
activity , and having an antiasthmatic action, a
bronchodilator action, an antiallergic action, an anti-itching
action, etc.
Background Art
Adenosine binds to adenosine receptors at the cell
surfaces to cause various biological response.
The four subtypes of adenosine receptors, including A1,
A2a, A2b and A3 are known to be present (Pharmacological
Reviews, Vol. 46, No. 2, p143, 1994). It is indicated that
adenosine A3 receptors are highly represented in the human
pulmonary tissue (Proc. Natl. Acad. Sci. USA, Vol. 90,
p10365, 1993), and are related to acceleration of the
release of various mediators from mast cells (J. Biol. Chem.,
Vol. 268, No. 23, p16887, 1993). It is also disclosed in
WO 95/11681 that compounds antagonistic to A3 receptors
inhibit mast cell degranulation by adenosine and are
expected as antiasthmatics. It is further disclosed in GB
2288733A that compounds antagonistic to A3 receptors inhibit
the activation of eosinophil by adenosine and are expected
as antiasthmatics. Namely, compounds antagonistic to
adenosine A3 receptors are expected as antiasthmatics.
Allergic diseases such as pruritus are known to be caused
by the release of mediators from mast cells due to various
types of stimulation [Standard Dermatology, Vol. 4. p160
(Igakushoin), 1994]. Therefore, compounds antagonistic to A3
receptors are also expected to inhibit the release of
mediators from mast cells and exhibit an antiallergic action
such as an antipruritic action or the like.
A paper ( J. Med. Chem., Vol. 23, p1188, 1980)
discloses that as condensed purine compounds, compounds
represented by formula (A) have a weak bronchodilator action.
Also Japanese Unexamined Patent Publication No. 91-204880
discloses that compounds represented by formula (B) exhibit
a diuretic action and a weak antiasthmatic action.
Disclosure of Invention
An object of the present invention is to provide novel
condensed purine derivatives exhibiting adenosine A3 receptor
antagonizing activity , and having an antiasthmatic action,
a bronchodilator action, an antiallergic action, an
antiitching action, etc.
The present invention relates to condensed purine
compounds and pharmacologically acceptable salts thereof
represented by the following formula (I):
(wherein R
1 represents substituted or unsubstituted aryl or a
substituted or unsubstituted aromatic heterocyclic group; R
2
represents hydrogen, lower alkyl, alicyclic alkyl,
substituted or unsubstituted aralkyl, substituted or
unsubstituted aryl, or a substituted or unsubstituted
aromatic heterocyclic group; R
3 represents hydrogen, lower
alkyl, or substituted or unsubstituted aralkyl; X
1 and X
2 are
the same or different and each represents hydrogen, lower
alkyl, substituted or unsubstituted aralkyl, or substituted
or unsubstituted aryl; and n represents an integer of 0 to
3).
Hereinafter, compounds represented by formula (I) are
referred to as "compounds (I)". This applies to compounds
represented by other formulas.
In the definition of each of the groups in formula (I),
lower alkyl includes straight or branched groups having 1 to
9 carbon atoms, such as methyl, ethyl, propyl, isopropyl,
butyl, isobutyl, sec-butyl, tert-butyl, pentyl, neopentyl,
hexyl, heptyl, octyl, nonyl, and the like. Alicyclic alkyl
includes groups having 3 to 8 carbon atoms, such as
cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,
cycloheptyl, cyclooctyl, and the like. Aralkyl includes
groups having 7 to 15 carbon atoms, such as benzyl,
phenethyl, benzhydryl; naphthylmethyl, and the like. Aryl
includes phenyl, naphthyl, indenyl, anthranyl, and the like.
Aromatic heterocyclic groups include furyl, thienyl,
pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl,
oxazolyl, thiazolyl, pyridyl, pyrazinyl, pyrimidinyl,
pyridazinyl, triazinyl, indolyl, indazolyl, benzoimidazolyl,
benzoxazolyl, benzothiazolyl, quinolyl, isoquinolyl,
phthalazinyl, naphthyrizinyl, quinoxalinyl, quinazolinyl,
cinnolinyl, purinyl, and the like.
Each of substituted aryl, aralkyl, and aromatic
heterocyclic groups has 1 to 3 substituents which are the
same or different, and which are selected from, substituted
or unsubstituted lower alkyl, substituted or unsubstituted
lower alkenyl, substituted or unsubstituted lower alkinyl,
substituted or unsubstituted aralkyl, substituted or
unsubstituted aryl, hydroxy, substituted or unsubstituted
lower alkoxy, substituted or unsubstituted aralkyloxy,
substituted or unsubstituted aryloxy, lower alkxoylcarbonyl,
lower alkylthio, lower alkylsulfonyl, carboxy, carbamoyl,
lower alkanoyl, aroyl, halogen, nitro, amino, mono- or di-lower
alkylamine, cyano, trifluoromethyl, and the like. Of
these substituents, lower alkyl and the lower alkyl moiety
of each of lower alkoxy, lower alkoxycarbonyl, lower
alkylthio, lower alkylsulfonyl, lower alkanoyl, and mono- or
di-alkylamino are defined in the same way as defined above
for lower alkyl. Aralkyl and the aralkyl moiety in the of
aralkyloxy are defined in the same as defined above for
aralkyl. Aryl and the aryl moiety in each of aryloxy and
aroyl are defined in the same way as defined above for aryl.
Lower alkenyl includes straight or branched groups having
2 to 6 carbon atoms, such as vinyl, ally, 1-propenyl,
methacryl, butenyl, crotyl, pentenyl, hexenyl, and the like.
Lower alkynyl includes straight or branched groups having
2 to 6 carbon atoms, such as ethynyl, propynyl, butynyl,
pentynyl, hexynyl, and the like.
Halogen includes fluorine, chlorine, bromine and iodine
atoms. Each of substituted lower alkyl, substituted lower
alkenyl, substituted lower alkynyl and substituted lower
alkoxy has 1 to 3 are selected from which are the same or
different and which are, for example, carboxy, sulfo,
phospho, lower alkyl esters, aralkyl eaters or aryl esters
thereof, hydroxy, halogen and the like. Each of the lower
alkyl moiety of lower alkyl esters, the aralkyl moiety of
aralkyl esters and the aryl moiety in aryl esters is defined
in the same way as defined above. Halogen is defined as
the same as the above. Each of substituted aralkyl,
substituted aryl, substituted aralkyloxy and substituted
aryloxy has 1 to 3 substituents which are the same or
different, and are selected from lower alkyl, hydroxy,
halogen and the like. Lower alkyl and halogen are defined
as the same as the above.
As compounds (I), compounds having hydrogen as R3 are
preferable, and compounds having substituted or
unsubstituted phenyl as R1 are preferable. Where R1 is
substituted phenyl, compounds having 1 to 3 substituents in
substituted phenyl as R1, which are the same or different and
are selected from halogen, lower alkyl, lower alkoxy and
substituted lower alkenyl, are prefered, and halogen is
particularly prefered. As the substituent of substituted
lower alkenyl, lower alkoxycarbonyl is prefered.
Pharmacologically acceptable salts of compounds (I)
include pharmacologically acceptable metal salts, ammonium
salts, organic amine addition salts, amino acid addition
salts, acid addition salts, and the like.
Pharmacologically acceptable metal salts of compounds
(I) include alkali metal salts such as sodium salts,
potassium salts, and the like; alkaline earth metal salts
such as magnesium salts, calcium salts, and the like;
aluminum salts; zinc salts; and the like.
Pharmacologically acceptable ammonium salts include ammonium,
tetramethylammonium, and the like. Pharmacologically
acceptable organic amine addition salts include addition
salts of morpholine, piperidine, and the like.
Pharmacologically acceptable amino acid addition salts
include addition salts of lysine, glycine, phenylalanine,
and the like. Pharmacologically acceptable acid addition
salts include inorganic acid salts such as hydrochlorides,
sulfates, phosphates, and the like; organic acid salts such
as acetates, maleates, fumarates, tartrates, citrates, and
the like.
The process for producing compounds (I) will be
described below.
Process 1
Compounds (I) can be produced according to the
following reaction steps:
(wherein R
1, R
2, R
3, X
1, X
2 and n are defined in the same way
as defined above).
Step 1
Compound (IV) can be obtained by reacting compound (II)
with 1 to 10 equivalents, preferably 4 to 6 equivalents, of
compound (III) without a solvent or in an appropriate
solvent. Examples of the solvent include dimethylamides
such as dimethylformamide, dimethylacetamide, and the like;
ketones such as acetone, methyl ethyl ketone, and the like;
aromatic hydrocarbons such as toluene, xylene, and the like;
halogenated hydrocarbons such as dichloromethane, 1,1,2,2-tetrachloroethane,
and the like; dimethyl sulfoxide; and the
like. Dimethyl sulfoxide is prefered. These solvents are
used singly or in mixture. The reaction is carried out at
50 to 180°C for 5 minutes to 24 hours.
Compound (II) as a starting material can be obtained by
a known method (J. Chem. Soc. Perkin I, p739, 1973), or in
accordance with this method.
Step 2
Compound (I) can be obtained by treating compound (IV)
with 1 equivalent to an excessive amount, preferably
excessive amount, of halogenating agent such as thionyl
chloride, phosphorus oxychloride, or the like, or an
inorganic salt such as hydrochloric acid, hydrobromic acid,
hydroiodic acid, phosphoric acid, or the like without a
solvent or in an appropriate solvent. The Examples of
solvents includes, for example, halogenated hydrocarbons
such as methylene chloride, chloroform, dichloroethane, and
the like; dimethylformamide; dimethyl sulfoxide; and the
like. Chloroform is prefered. These solvents are used
singly or in mixture. The reaction is carried out at - 10
to 150°C, preferably 50 to 70°C, for 5 minutes to 24 hours.
Process 2
Of compounds (I), compound (Ia) in which R
1 is β-lower
alkoxycarbonylstyryl, β-aralkyloxycarbonylstyryl or β-aryloxycarbonylstyryl,
and R
3 is hydrogen, or compound (Ib)
in which R
1 is β-carboxystyryl and R
3 is hydrogen can also be
produced in accordance with the following reaction steps:
(wherein R
4 represents alkyl, aralkyl or aryl, and R
2, X
1, X
2
and n are defined in the same way as defined above).
In the definition of R4, each of lower alkyl, aralkyl
and aryl is defined in the same way as defined above.
Step 3
Compound (V) can be obtained by reacting compound (Ic)
which is compound (I) in which R1 is bromophenyl, and R3 is
hydrogen, with 1 to 3 equivalents of 2-(chloromethoxy)
ethyltrimethylsilane in the presence of 3 to 10 equivalents
of an appropriate base without a solvent or in an
appropriate solvent. Examples of the base include
triethylamine, diisopropylethylamine, or the like.
Triethylamine is prefered. Examples of the solvent include
dimethylammides such as dimethylformamide, dimethylacetamide,
and the like; ketones such as acetone, methyl ethyl ketone,
and the like; aromatic hydrocarbons such as toluene, xylene,
and the like; ethers such as tetrahydrofuran, dioxane, ether,
and the like; pyridine; acetonitrile; dimethyl sulfoxide;
and the like. Tetrahydrofuran or dimethyl sulfoxide is
preferably used. The reaction is generally carried out at
0 to 50°C, preferably at room temperature, for 30 minutes to
24 hours.
Step 4
Compound (VII) can be obtained by reacting compound (V)
with one equivalent to an excessive amount of compound (VI)
in the presence of 1 to 5 equivalents of an appropriate base
and a catalytic amount of palladium catalyst without a
solvent or in an appropriate solvent. Examples of the base
include triethylamine, diisopropylamine, pyridine, potassium
carbonate, sodium carbonate, sodium hydrogen carbonate, and
the like. Triethylamine is prefered. Examples of the
palladium catalyst include tetrakistriphenylphosphine
palladium, dichloropalladium, palladium acetate, and the
like. Dichlorobistriphenylphosphine palladium is preferably
used. Examples of the solvent include dimethyamides such
as dimethylformamide, dimethylacetamide, and the like;
ketones such as acetone, methyl ethyl ketone, and the like;
aromatic hydrocarbons such as toluene, xylene, and the like;
ethers such as tetrahydrofuran, dioxane, ether, and the
like; acetonitrile; dimethyl sulfoxide; and the like.
Dimethylformamide is preferably used. The reaction is
generally carried out at 0 to 150°C, preferably 90 to 110°C,
for 10 minutes to 24 hours.
Step 5
Compound (Ia) can be obtained by treating compound
(VII) with an inorganic acid such as hydrochloric acid or
the like without a solvent or in an appropriate solvent.
Examples of the solvent include alcohols such as ethanol,
methanol, propanol, and the like; dimethylamides such as
dimethylformamide, dimethylacetamide, and the like; ketones
such as acetone, methyl ethyl ketone, and the like; ethers
such as tetrahydrofuran, dioxane, ether, and the like;
halogenated hydrocarbons such as methylene chloride,
chloroform, dichloroethane, and the like; acetonitrile;
dimethyl sulfoxide; water; and the like. Ethanol or
dioxane is preferably used. The reaction is generally
carried out at 0 to 100°C, preferably room temperature, for
5 minutes to 24 hours.
Compound (Ia) can also be obtained by the following
method:
Compound (Ia) can be obtained by treating compound
(VII) with tetrabutylammonium fluoride or the like in an
appropriate solvent. Examples of the solvent include
alcohols such as ethanol, methanol, propanol, and the like;
dimethylamides such as dimethylformamide, dimethylacetamide,
and the like; ketones such as acetone, methyl ethyl ketone,
and the like; ethers such as tetrahydrofuran, dioxane, ether,
and the like; acetonitrile; dimethyl sulfoxide; water; and
the like. Tetrahydrofuran is preferably used. The reaction
is generally performed at 0 to 80°C, preferably room
temperature, for 5 minutes to 24 hours.
Step 6
Compound (Ib) can be obtained by treating compound (Ia)
with a 1 to 10N sodium hydroxide aqueous solution without a
solvent or in an appropriate solvent. Examples of the
solvent include alcohols such as ethanol, methanol, propanol,
and the like; dimethylamides such as dimethylformamide,
dimethylacetamide, and the like; ketones such as acetone,
methyl kethyl ketone, and the like; ethers such as
tetrahydrofuran, dioxane, ether, and the like; acetonitrile;
dimethyl sulfoxide; water; and the like. Ethanol or
dioxane is preferably used. The treatment is generally
effected at 0 to 100°C, preferably at room temperature, for
5 minutes to 24 hours.
Of compounds (I), compound (Id) in which R1 is β-lower
alkoxycarbonylstyryl, β-aralkyloxycarbonylstyryl or β-aryloxycarbonylstyryl,
and R3 is lower alkyl or substituted
or unsubstituted aralkyl can also be produced from a
compound as compound (I) in which R1 is bromophenyl and R3 is
lower alkyl or substituted or unsubstituted aralkyl in
accordance with the process of Step 4. Of compounds (I),
compound (Ie) in which R1 is β-carbonylstyryl and R3 is lower
alkyl or substituted or unsubstituted aralkyl can also be
produced from compound (Id) in accordance with the process
of Step 6.
The intermediate and target compound in each of the
above processes can be isolated and purified by a
purification method generally used in synthetic organic
chemistry, for example, neutralization, filtration,
extraction, washing, drying, concentration,
recrystallization, various chromatographic methods. The
intermediates can be supplied to the subsequent reaction
without particular purification.
In order to obtain salts of compounds (I), a general
method of synthetic organic chemistry may be used. For
example, when compounds (I) are obtained as salts, the salts
may be purified, and when compounds (I) are obtained in a
free form, compounds (I) may be dissolved or suspended in an
appropriate solvent, and then an acid or base may be added
to form salts.
Some compounds (I) have geometric isomers or optical
isomers. The present invention include all possible
stereoisomers including geometric isomers and optical
isomers, and mixtures thereof.
Some compounds (I) or pharmacologically acceptable
salts thereof are present in the form of an adduct with
water or one of various solvents. The present invention
include these adducts.
Table 1 shows examples of compounds (I). In this
table, compounds of Compound No. 1 to 38 correspond to
compounds obtained in Examples 1 to 38, respectively, which
will be described below.
The pharmacological actions of compounds (I) will be
described with reference to test examples.
Test Example 1: Test of adenosine A3 receptor binding
This test was carried out according to the method
which was a slightly modified method of Linden et
al.(International Application No. WO 95/11681).
The transfected HEK293 cells that expressed the human
adenosine A3 receptors were homogenized in 5 mM
tris(hydroxymethyl)aminomethane hydrochloric acid buffer
containing 5 mM magnesium chloride (pH 7.6) by a Teflon
homogenizer ( Iuchiseieido Corp.). The resultant
suspension was centrifuged (4000 x g, 20 minutes), and a 50
mM tris(hydromethyl)aminomethane/10 mM magnesium chloride/hydrochloric
acid buffer (pH 7.6) (referred to as "the Tris-HCl
buffer" hereinafter) was added to the precipitate to
generate the cell suspension ( the protein concentration
0.25 mg/ml). To the cell suspension was added adenosine
deaminase so that the concentration was 2 U/ml, and the
resultant mixture was used in the following binding
experiment.
10 µl (final concentration 0.1 nM) of 125I labeled 6-(3-iodo-4-aminobenzyl)
adenosine-5'-N-methyluronamide ([125I]AB-MECA:
2000 Ci/mmol; Amersham Corp.) and 10 µM of test
compound were added to the cell suspension (80 µl). After
incubation at 25°C for 120 minutes, the reaction mixture was
rapidly filtered with a glass fiber filter (GF/B; Whatman
Corp.) treated with 0.3% polyethyleneimine, and immediately
washed with 5 ml of ice-cooled Tris-HCl buffer three times.
The glass fiber filter was transferred to a polypropylene
tube, and the radioactivity was measured by a gamma counter
( Packard Corp.).
The rate of inhibition of adenosine A
3 receptor binding
([
125I]AB-MECA) of a test compound was calculated by the
following equation:
(Rate of inhibition)=(A-B)/(C-D) x 100
A: Amount of binding in the presence of the test compound B: Amount of non-specific binding C: Amount of total binding D: Amount of non-specific binding
(Note) The amount of total binding means the binding
radioactivity of [125I]AB-MECA in the absence of a test
compound. The amount of non-specific binding means the
binding radioactivity of [125I]AB-MECA in the presence of 100
µM N6-[(R)-phenylisopropyl] adenosine ( Sigma Corp.) The
amount of binding in the presence of a test compound means
the binding radioactivity of [125I]AB-MECA binding in the
presence of a test compound at each concentration.
The result is shown in Table 2.
Compound No. | The rate of inhibition (%) 10-8M/10-7M |
1 | 88/97 |
2 | 29/55 |
3 | 65/96 |
4 | 73/90 |
5 | 110/110 |
6 | 98/100 |
8 | 100/96 |
13 | 75/76 |
14 | 29/55 |
15 | 21/66 |
16 | 17/92 |
17 | 36/70 |
25 | 94/97 |
26 | 85/110 |
32 | 84/110 |
33 | 89/95 |
35 | 94/52 |
Compounds (I) or pharmacologically acceptable salts
thereof exhibited strong adenosine A3 acceptor antagonising
activity . Therefore, a medicine containing one of
compounds (I) as an effective ingredient is effective for
allergic diseases and asthma which are caused by
hyperactivity of adenosine A3 acceptors.
Test Example 2: Test of inhibition of compound 48/80 induced
pruritic action
It is known that compound 48/80 exhibits an pruritic
action (European Journal of Pharmacology, Vol. 275, pp229-233,
1995). A group consisting of 10 ddy mice (Japanese
SLC) having a body weight of 10 to 21 g was used in the test.
After compound 5 was orally administered, 0.5 mg/kg of
compound 48/80 was subcutaneously administered in a volume
of 0.1 ml per 20 g. 10 minutes after administration of
compound 48/80, the number of scratching behavior was
measured for 10 minutes. The rate of inhibition of the
group of mice administered with compound 5 relative to the
number of scratching behavior of a control group was
calculated, and ED50 was calculated from the rate of
inhibition.
The results are shown in Table 3.
Compound | No. of animal | Dose (mp/kg, p.o.) | (A) | (B) | ED50 |
Normal Control | 10 | | 1.60±0.64 |
Positive Control | 10 | | 16.20±3.56 |
Compound 5 | 10 | 30 | 10.70±4.45 | 34.0% |
10 | 100 | 7.60±3.12 | 53.1% | 96.5mg/kg |
10 | 300 | 6.00±2.88 | 63.0% |
(A):The number of scratching behavior/ 10minutes (B):The rate of inhibition (%) |
Compound 5 exhibited its inhibitory action on the
compound 48/80 induced itching.
Test example 3: Action on acute toxicity
A group consisting of three ddY mice (Japanese SLC)
having a body weight of 19 to 21 g was used. One week
after oral administration of compound 5, death of the mice
was observed.
After oral administration of 1000 mg/kg of compound 5,
no death was observed in the mice.
Although compounds (I) or pharmacologically acceptable
salts thereof can be administered singly, the compounds are
preferably provided as medical formulations. Also these
medical formations are used for animals and humans.
A pharmaceutical composition according to the present
invention can contains, as an active ingredient, compounds
(I) or pharmacologically acceptable salts thereof singly or
in a mixture with any other active ingredient for different
other treatment. Such a medical formulation is produced by
any desired method well known in the technical field of
pharmaceutics after an active ingredient is mixed with at
least one pharmacologically acceptable carrier.
As the administration route, a route which is the most
effective for intended treatment is preferably used, and an
oral or parenteral route, for example, intraoral,
tracheobronchial, intrarectal, subcutaneous, intramuscular
or intravenous administration, can be used.
As the administration form, a nebula, a capsule, a
tablet, granules, syrup, an emulsion, a suppository, an
injection, ointment, a tape, and the like can be used.
Liquid preparations suitable for oral administration,
such as an emulsion and syrup, can be produced by using
water, sucrose, sorbitol, saccharide such as fructose or the
like; glycol such as polyethylene glycol, propylene glycol,
or the like; oil such as olive oil, soybean oil, or the
like; a preservative such as p-hydroxybenzoate or the like;
and flavor such as a strawberry flavor, a peppermint flavor,
or the like. A capsule, a tablet, a powder and granules
can be produced by using an excipient such as lactose,
glucose, sucrose, mannitol, or the like; a disintegrator
such as starch, sodium alginate, or the like; a lubricant
such as magnesium stearate, talc, or the like; a binder such
s polyvinyl alcohol, hydroxypropyl cellulose, gelatin, or
the like; a surfactant such as a fatty acid ester or the
like; and a plasticizer such as glycerin, or the like.
Formulations suitable for parenteral administration
comprise a sterilized aqueous agent containing an active
compound which is preferably isotonic to the blood of a
recipient person. For example, for an injection, an
injection solution is prepared by using a salt solution, a
glucose solution or a carrier comprising a mixture of brine
and a glucose solution. Formulations for entral
administration are prepared by using a carrier, e.g., cacao
butter, hydrogenated fat, hydrogenated carboxylic acid, or
the like, and provided as suppositories. A nebula is
prepared by using an active compound or a carrier which
disperses the active compound as fine particles and
facilitates absorption without irritating the oral cavity
and the airway mucous membrane of a recipient person.
Examples of the carrier include lactose, glycerin and the
like. Depending upon the properties of the active compound
and the carrier used, formulations such as aerosol, dry
powder, and the like can be formed.
To these parenteral agents can be added as an auxiliary
ingredient at least one selected from glycols, oils, flavors,
preservatives, excipients, disintegrators, lubricants,
binders, surfactants, and plasticizers, which are examples
for oral agents.
Although the effective amount and the number of
administrations of compounds (I) or pharmacologically
acceptable salts thereof vary depending upon the
administration form, the age and body weight of a patient,
symptoms to be treated, or severity, 1 to 50 mg/kg is
preferably administered in 3 to 4 divided doses per day.
However, such a dose varies with the above-described various
conditions.
Modes for Carrying Out the Invention
Examples, reference examples and formulation examples
are described below.
Example 1
2-(p-Bromophenyl)-4-ethyl-1,4,7,8-tetrahydro-5H-imidazol[2.1-i]purine-5-one
hydrochloride (Compound 1)
3.5 g (9.61 mmol) of compound
c obtained in Reference
Example 3 was dissolved in 10 ml of dimethyl sulfoxide, and
2.86 ml (48.0 mmol) of ethanolamine was added to the
resultant solution, followed by stirring at 150°C for 2
hours. After the reaction solution was cooled to room
temperature, the solution was neutralized by adding water
and 2N hydrochloric acid, and the thus-obtained crystals
were collected. The crystals were washed with water and
then ether, and dried under reduced pressure. To the thus-obtained
crystals were added 30 ml of chloroform and 2.8 ml
(38.4 mmol) of thionyl chloride, followed by heating under
reflux for 2 hours. After the reaction solution was cooled
to room temperature, 100 ml of ether was added to the
solution, and the thus-precipitated crystals were collected
off. The crystals obtained were washed with ether to
obtain 3.66 g (yield: 87%) of titled compound 1 as pale
yellow crystals.
1H-NMR(DMSO-d6)δ(ppm); 8.04(d, J=8.4Hz, 2H), 7.83(d, J=8.4Hz, 2H),
4.36-3.76(m, 6H), 1.30(t, J=6.9Hz, 3H) MS(m/e); 361, 359(M+) IR(KBr, cm-1); 1718, 1682, 1600, 1475 Melting point; > 300°C
Elementary analysis; For C15H14N5OBr 2.1 HCl, |
Calculated (%): | C 41.25, | H 3.72, | N 16.03 |
Found (%): | C 41.36, | H 3.47, | N 15.86 |
Example 2
2-(p-Bromophenyl)-4-ethyl-1,4,7,8,9-hexahydropyrimido
[2,1-i]purine-5-one hydrochloride (Compound 2)
Example 1 was repeated except that 4.0 g (11.0 mmol) of
compound
c obtained in Reference Example 3, 4.2 ml (54.6
mmol) of 3-aminopropanol, and 2.3 ml (31. 6 mmol) of thionyl
chloride were used to obtain 3.52 g (yield: 71%) of titled
compound 2 as white crystals.
1H-NMR(DMSO-d6)δ(ppm); 8.03(d, J=8.4Hz, 2H), 7.57(d, J=8.4Hz, 2H),
4.11(q, J=6.9Hz, 2H), 3.98-3.89(m, 2H), 3.51-3.40(m, 2H), 2.12-2.01(m,
2H), 1.28(t, J=6.9Hz, 3H) MS(m/e); 375, 373 (M+) IR(KBr, cm-1); 1682, 1600, 1478, 1418 Melting point; > 300°C
Elementary analysis; For C16H16N5OBr 2.1 HCl, |
Found (%): | C 42.81, | H 3.93, | N 15.50 |
Calculated (%): | C 42.63, | H 4.05, | N 15.54 |
Example 3
2-[p-Bromophenyl)-4-ethyl-8-methyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
hydrochloride (Compound 3)
Example 1 was repeated except that 4.0 g (10.95 mmol)
of compound
c obtained in Reference Example 3, 4.3 ml (54.8
mmol) of 2-aminopropanol, and 2.1 ml (28.2 mmol) of thionyl
chloride were used to obtain 3.92 g (yield: 79%) of titled
compound 3 as yellow crystals.
1H-NMR(DMSO-d6)δ(ppm); 8.02(d, J=8.4Hz, 2H), 7.84(d, J=8.4Hz, 2H),
4.36-4.05(m, 3H), 3.63-3.46(m, 2H), 1.33-1.21(m, 6H) MS(m/e); 375, 373 (M+) IR(KBr, cm-1); 1682, 1658, 1600, 1478, 1418 Melting point; 256.0 - 259.5°C
Elementary analysis; For C16H16N5OBr 2.1 HCl, |
Found (%): | C 42.83, | H 4.20, | N 15.41 |
Calculated(%): | C 42.63, | H 4.05, | N 15.51 |
Example 4
2-(p-Bromophenyl)-4,8-diethyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
hydrochloride (Compound 4)
Example 1 was repeated except that 2.46 g (6.76 mmol)
of compound
c obtained in Reference Example 3, 3.19 ml (33.8
mmol) of 2-aminobutanol, and 1.5 ml (20.3 mmol) of thionyl
chloride were used to obtain 2.53 g (yield: 83%) of titled
compound 4 as pale yellow crystals.
1H-NMR(DMSO-d6)δ(ppm); 10.05(d(br), J=9.0Hz, 1H), 8.04(d, J=8.4Hz,
2H), 7.82(d, J=8.4Hz, 2H), 4.26-4.16(m, 1H), 4.10(q, J=6.9Hz, 2H),
3.66-3.47(m, 2H), 1.70-1.53(m, 2H), 1.31(t, J=6.9Hz, 3H), 0.96(t,
J=7.4Hz, 3H) MS(m/e); 389, 387 (M+) IR(KBr, cm-1); 1718, 1680, 1590, 1475 Melting point; 237.6 - 238.5°C
Elementary analysis; For C17H18N5OBr 2.1 HCl, |
Found(%): | C 43.91, | H 4.74, | N 15.04 |
Calculated (%): | C 43.93, | H 4.36, | N 15.07 |
Example 5
2-(p-Bromophenyl)-4-propyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
hydrochloride (Compound 5)
Example 1 was repeated except that 10 g (26.4 mmol) of
compound
f obtained in Reference Example 6, 7.5 ml (132
mmol) of aminoethanol, and 5.36 ml (73.5 mmol) of thionyl
chloride were used to obtain 10.0 g (yield: 87%) of titled
compound 5 as light brown crystals.
1H-NMR(DMSO-d6)δ(ppm); 10.10(s(br), 1H) 8.01(d, J=7.9Hz, 2H), 7.84(d,
J=8.3Hz, 2H), 4.28-3.81(m, 6H), 1.76(q, J=7.3Hz, 2H), 0.94(t, J=7.3Hz,
3H) MS(m/e); 375, 373 (M+) IR(KBr, cm-1); 1705, 1681, 1520, 1182 Melting point; 265.5 - 268.2°C
Elementary analysis; For C16H16N5OBr 2.2 HCl, |
Found (%): | C 42.30, | H 3.89, | N 15.23 |
Calculated (%): | C 42.29, | H 4.04, | N 15.41 |
Example 6
2-(p-Bromophenyl)-4-propyl-1,4,7,8-hexahydropyrimido
[2,1-i]purine-5-one hydrochloride (Compound 6)
Example 1 was repeated except that 10 g (26.4 mmol) of
compound
f obtained in Reference Example 6, 10.1 ml (132
mmol) of 3-aminopropanol, and 5.65 ml (77.4 mmol) of thionyl
chloride were used to obtain 10.36 g (yield: 84%) of titled
compound 6 as white crystals.
1H-NMR(DMSO-d6)δ(ppm); 8.03(d, J=7.9Hz, 2H), 7.84(d, J=8.2Hz, 2H)
4.12-3.30(m, 2H), 3.84-3.30(m, 4H), 2.20-2.08(m, 2H), 1.81-1.70(m,
2H), 0.94(t, J=7.3Hz, 3H) MS(m/e); 389, 387 (M+) IR(KBr, cm-1); 1678, 1600, 1468, 1418 Melting point; > 300°C
Elementary analysis; For C17H18N5OBr 2.2 HCl, |
Found (%): | C 43.63, | H 4.20, | N 14.88 |
Calculated (%): | C 43.59, | H 4.35, | N 14.95 |
Example 7
2-(p-Bromophenyl)-8-methyl-4-propyl-1,4,7,8-tetrahydro-5H-imidazo[2.1-i]purine-5-one
hydrochloride (Compound 7)
Example 1 was repeated except that 2 g (5.29 mmol) of
compound
f obtained in Reference Example 6, 2.11 ml (26.5
mmol) of 2-aminopropanol, and 1.59 ml (21.85 mmol) of
thionyl chloride were used to obtain 1.58 g (yield: 64%) of
titled compound 7 as yellow crystals.
1H-NMR(DMSO-d6)δ(ppm); 8.10-8.00(m, 2H), 7.83(d, J=6.9Hz, 2H), 4.40-3.70(m,
5H), 1.76(q, J=6.9Hz, 2H), 1.40(t, J=6.4Hz, 3H), 0.94(t,
J=7.4Hz, 3H) MS(m/e); 389, 387 (M+) IR(KBr, cm-1); 2970, 1680, 1600, 1475 Melting point; 265.5 - 267.5°C
Elementary analysis; For C18H18N5OBr 1.9 HCl, |
Found (%): | C 46.27, | H 4.68, | N 14.67 |
Calculated (%): | C 46.04, | H 4.27, | N 14.91 |
Example 8
2-(p-Bromophenyl)-8-ethyl-4-propyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
hydrochloride (Compound 8)
Example 1 was repeated except that 10 g (26.4 mmol) of
compound
f obtained in Reference Example 6, 12.47 ml (132
mmol) of 2-aminobutanol, and 5.17 ml (70.9 mmol) of thionyl
chloride were used, to obtain 9.57 g (yield: 77%) of titled
compound 8 as yellow crystals.
1H-NMR(DMSO-d6)δ(ppm); 8.04(d, J=8.3Hz, 2H), 7.84(d, J=8.6Hz, 2H),
4.52-4.30(m, 1H), 4.13-3.72(m, 4H), 1.85-1.68(m, 4H), 1.03-0.91(m,
6H) MS(m/e); 339 (M+) IR(KBr, cm-1); 1715, 1675, 1600, 1475, 1418 Melting point; 255.5 - 258.5°C
Elementary analysis; For C18H20N5OBr 2HCl, |
Found (%): | C 45.47, | H 4.80, | N 14.60 |
Calculated (%): | C 45.49, | H 4.67, | N 14.47 |
Example 9
2-(o-Bromophenyl)-4-propyl-1,4,7,8-tetrahydro-5H-imidazo
[2,1-i] purine-5-one hydrochloride (Compound 9)
Example 1 was repeated except that 3.0 g (7.94 mmol) of
compound
i obtained in Reference Example 9, 2.39 ml (39.7
mmol) of aminoethanol, and 2.27 ml (31.1 mmol) of thionyl
chloride were used, to obtain 2.53 g (yield: 65%) of titled
compound 9 as white crystals.
1H-NMR(DMSO-d6)δ(ppm); 7.88-7.75(m, 2H), 7.64-7.52(m, 2H), 4.08-3.83(m,
6H), 1.79-1.68(m, 2H), 0.93(t, J=7.4Hz, 3H) MS(m/e); 375, 373 (M+) IR(KBr, cm-1); 1718, 1677, 1627, 1571 Melting point; 180.2 - 180.7°C
Elementary analysis; For C16H16N5OBr 2.0HCl, |
Found (%): | C 43.20, | H 4.13, | N 15.47 |
Calculated (%): | C 42.98, | H 4.06, | N 15.66 |
Example 10
4-Propyl-2-(p-tolyl)-1,4,7,8-tetrahydro-5H-imidazo
[2,1-i]purine-5-one hydrochloride (Compound 10)
Example 1 was repeated except that 1.2 g (3.82 mmol) of
compound m obtained in Reference Example 12, 1.13 ml (19.1
mmol) of aminoethanol, and 3 ml (41.1 mmol) of thionyl
chloride were used, to obtain 1.07 g (yield: 73%) of titled
compound 10 as brown crystals.
1H-NMR(DMSO-d6)δ(ppm); 8.03-7.97(m, 2H), 7.42(d, J=7.9Hz, 2H), 4.20-3.85(m,
6H), 2.40(s, 3H), 1.77(q, J=7.4Hz, 2H), 0.94(t, J=7.4Hz, 3H) MS(m/e); 309 (M+) IR(KBr, cm-1); 2724, 1548, 1463, 1440 Melting point; > 300°C
Elementary analysis; For C17H19N5O 2.1HCl, |
Found (%): | C 53.07, | H 5.57, | N 17.95 |
Calculated(%): | C 52.91, | H 5.51, | N 18.15 |
Example 11
2-(o-Bromophenyl)-8-ethyl-4-propyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
hydrochloride (Compound 11)
Example 1 was repeated except that 2.0 g (5.29 mmol) of
compound
i obtained in Reference Example 9, 2.50 ml (26.5
mmol) of 2-aminobutanol, and 1.63 ml (22.3 mmol) of thionyl
chloride were used, to obtain 1.64 g (yield: 64%) of titled
compound 11 as white crystals.
1H-NMR(DMSO-d6)δ(ppm); 7.89-7.75(m, 2H), 7.65-7.50(m, 2H), 4.51-4.34(m,
2H), 4.08-3.73(m, 3H), 1.81-1.68(m, 4H), 1.07-0.90(m, 6H) MS(m/e); 403, 401 (M+) IR(KBr, cm-1); 1702, 1672, 1623, 1540 Melting point; 160.0 - 161.0°C
Elementary analysis; For C18H20N5OBr 2.3HCl, |
Found (%): | C 44.25, | H 4.41, | N 14.76 |
Calculated (%): | C 44.47, | H 4.62, | N 14.41 |
Example 12
8-Ethyl-4-propyl-2-(p-tolyl )-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
hydrochloride (Compound 12)
Example 1 was repeated except that 1.2 g (3.82 mmol) of
compound
m obtained in Reference Example 12, 1.81 ml (19.1
mmol) of 2-aminobutanol, and 3.0 ml (41.1 mmol) of thionyl
chloride were used, to obtain 0.24 g (yield: 52%) of titled
compound 12 as white crystals.
1H-NMR(DMSO-d6)δ(ppm); 8.01(d, J=7.2Hz, 2H), 7.42(d, J=7.9Hz, 2H),
4.54-4.37(m, 1H), 4.16-3.75(m, 4H), 2.40(s, 3H), 1.82-1.73(m 4H),
1.02-0.92(m 6H) MS(m/e); 337 (M+) IR(KBr, cm-1); 1716, 1635, 1621, 1567 Melting point; 169.8 -170.2°C
Elementary analysis; For C19H23N5O 2.3HCl, |
Found(%): | C 54.46, | H 6.16, | N 16.28 |
Calculated(%): | C 54.17, | H 6.05, | N 16.62 |
Example 13
Ethyl (E)-4-(4-ethyl-1,4,7,8-tetrahydro-5H-imidazo
[2,1-i]purine-5-one-2-yl)cinnamate (Compound 13)
3.66 g (8.47 mmol) of compound 1 obtained in Example 1
was suspended in 50 ml of tetrahydrofuran, and 7.1 ml (50.8
mmol) of triethylamine and 4.5 ml (25.4 mmol) of 2-(chloromethoxy)ethyl
trimethylsilane were added to the
resultant suspension, followed by stirring at room
temperature overnight. After the solvent was distilled off,
chloroform and water were added to the residue to extract an
organic layer. The thus-obtained organic layer was dried
over anhydrous magnesium sulfate, and the solvent was
distilled off, followed by purification by silica gel column
chromatography (eluting solvent: 40% ethyl acetate-hexane)
to obtain 1.44 g (yield; 35%) of main product.
1.44 g (2.94 mmol) of the thus-obtaiend main product
was dissolved in 5 ml of dimethylformamide, and 4.1 ml (29.4
mmol) of triethylamine, 3.13 ml (29.4 mmol) of ethyl
acrylate and 103 mg (0.15 mmol) of
dichlorobistriphenylphosphine palladium were added to the
resultant solution, followed by stirring at 100°C for 8
hours. After the reaction solution was cooled to room
temperature, chloroform and water were added to the reaction
mixture to extract an organic layer. The thus-obtained
organic layer was dried over anhydrous magnesium sulfate,
and the solvent was distilled off, followed by purification
by silica gel column chromatography (eluting solvent: 40%
ethyl acetate-hexane) to obtain 890 mg (yield: 59%) of main
product.
To 1.0 g (1.96 mmol) of the main product were added 15
ml of ethanol and 10 ml of 2N hydrochloric acid, followed by
heating under reflux for 2 hours. After the reaction
solution was cooled to room temperature, the solution was
neutralized with a 2N sodium hydroxide aqueous solution, and
the precipitated crystals were collected. The crystals
obtained were purified by silica gel column chromatography
(eluting solvent: 2% methanol-chloroform), and then
recrystallized from ethanol to obtain 520 mg (total yield:
14%) of titled compound 13 as white crystals.
1H-NMR(CDCl3)δ(ppm); 8.18(d, J=8.4Hz, 2H), 7.70(d, J=16.3Hz, 1H),
7.58(d, J=8.4Hz, 2H), 6.47(d, J=15.8Hz, 1H), 4.34-4.15(m, 6H), 3.66(t,
J=8.9Hz, 2H), 1.43(t, J=6.9Hz, 3H), 1.35(t, J=7.4Hz, 3H) MS(m/e); 379 (M+) IR(KBr, cm-1); 1710, 1648, 1541, 1455 Melting point; 261.0 - 269.5°C
Elementary analysis; For C20H21N5O3 0.5H2O, |
Found (%): | C 61.90, | H 5.79, | N 17.74 |
Calculated (%): | C 61.84, | H 5.71, | N 18.03 |
Example 14
Ethyl (E)-4-(4-ethyl-1,4,5,7,8,9-hexahydropyrimido
[2,1-i] purine-5-one-2-yl)cinnamate (Compound 14)
2.11 g (4.72 mmol) of compound 2 obtained in Example 2
was suspended in 50 ml of tetrahydrofuran, and 2.6 ml (18.9
mmol) of triethylamine and 1.6 ml (9.44 mmol) of 2-(chloromethoxy)ethyl
trimethylsilane were added to the
resultant suspension, followed by stirring at room
temperature overnight. After the solvent was distilled off,
ethyl acetate and water were added to the residue to extract
an organic layer. The thus-obtained organic layer was
dried over anhydrous magnesium sulfate, and the solvent was
distilled off, followed by purification by silica gel column
chromatography (eluting solvent: 30% ethyl acetate-hexane)
to obtain 2.11 g (yield; 89%) of a main product.
2.11 g (4.20 mmol) of the thus-obtaiend main product
was dissolved in 5 ml of dimethylformamide, and 5.85 ml (42
mmol) of triethylamine, 4.46 ml (42 mmol) of ethyl acrylate
150 mg (0.21 mmol) of dichlorobistriphenylphosphine
palladium were added to the resultant solution, followed by
stirring at 100°C for 8 hours. After the reaction solution
was cooled to room temperature, chloroform and water were
added to the reaction solution to extract an organic layer.
The thus-obtained organic layer was dried over anhydrous
magnesium sulfate, and the solvent was distilled off,
followed by purification by silica gel column chromatography
(eluting solvent: 40% ethyl acetate-hexane) to obtain 1.54
mg (yield: 70%) of a main product.
To 1.67 g (3.19 mmol) of the product were added 15 ml
of tetrahydrofuran and 14.7 ml of a solution of 1M
tetrabutylammonium fluoride in tetrahydrofuran, followed by
heating under reflux for 6 hours. After the reaction
solution was cooled to room temperature, an ammonium acetate
aqueous solution and chloroform were added to the solution
to extract an organic layer. The thus-obtained organic
layer was washed with saturated saline, and dried over
anhydrous magnesium sulfate. After the solvent was
distilled off, the residue was purified by silica gel column
chromatography (eluting solvent: 2% ethanol-chloroform) to
obtain 720 mg (total yield: 36%) of titled compound 14.
1H-NMR(DMSO-d6)δ(ppm); 8.18(d, J=8.4Hz, 2H), 7.87(d, J=8.4Hz, 2H),
7.68(d, J=15.8Hz, 1H), 6.73(d, J=15.8Hz, 1H), 4.25-4.10(m, 4H),
3.99(t, J=6.9Hz, 2H), 2.82(t, J=7.9Hz, 2H), 1.99-1.85(m, 2H), 1.33-1.24(m,
6H) MS(m/e); 393 (M+)
Example 15
(E)-4-(4-Ethyl-1-4,5,7,8,9-hexahydropyrimido[2,1-i]-purine-5-one-2-yl)cinnamic
acid (Compound 15)
480 mg (1.22 mmol) of compound 14 obtained in Example
14 was suspended in 10 ml of ethanol, and 10 ml of 2N sodium
hydroxide aqueous solution was added to the resultant
suspension, followed by stirring at room temperature for 4
hours. The mixture was then neutralized with 2N
hydrochloric acid, and the precipitated crystals were
collected off, washed with water, and then recrystallized
from dimethylsulfoxide-water to obtain 112 mg (yield: 25%)
of titled compound 15 as yellow crystals.
1H-NMR(DHSO-d6)δ(ppm); 8.31(d, J=8.2Hz, 2H), 7.68(d, J=8.4Hz, 2H),
7.59(d, J=16.2Hz, 1H), 6.49(d, J=15.8Hz, 1H), 4.12(q, J=6.9Hz, 2H),
4.00-3.93(m, 2H), 3.45-3.25(m, 2H), 2. 11-2.00(m, 2H), 1.29(t, J=6.9Hz,
3H) MS(m/e); 379 (M+) IR(KBr, cm-1); 2970, 1715, 1660, 1380 Melting point; > 300°C
Elementary analysis; For C19H19N5O3 1.5H2O, |
Found (%): | C 58.23, | H 5.40, | N 17.63 |
Calculated (%): | C 58.16, | H 5.65, | N 17.85 |
Example 16
Ethyl (E)-4-(4,8-diethyl-1,4,7,8-tetrahydro-5H-imidazo-[2,1-i]purine-5-one-2-yl)cinnamate
(Compound 16)
5.5 g (11.9 mmol) of compound 4 obtained in Example 4
was suspended in 30 ml of dimethylformamide, and 8.31 ml
(59.7 mmol) of triethylamine and 4.22 ml (23.9 mmol) of 2-(chloromethoxy)ethyl
trimethylsilane were added to the
resultant suspension, followed by stirring at room
temperature for 3 hours. To the reaction solution were
added chloroform and water to extract an organic layer. The
thus-obtained organic layer was dried over anhydrous
magnesium sulfate, and the solvent was distilled off,
followed by purification by silica gel column chromatography
(eluting solvent: 20% ethyl acetate-hexane for the first
fraction, 30% ethyl acetate-hexane for the second fraction)
to obtain 2.08 g (total yield of the first and second
fractions; 34%) of a main product.
590 mg (1.14 mmol) of the thus-obtained main product
(first fraction) was dissolved in 5 ml of dimethylformamide,
and 1.59 ml (11.4 mmol) of triethylamine, 1.21 ml (11.4
mmol) of ethyl acrylate and 40 mg (0.06 mmol) of
dichlorobistriphenylphosphine palladium were added to the
resultant solution, followed by stirring at 100°C for 8
hours. After the reaction solution was cooled to room
temperature, chloroform and water were added to the reaction
solution to extract an organic layer. The thus-obtained
organic layer was dried over anhydrous magnesium sulfate,
and the solvent was distilled off, followed by purification
by silica gel column chromatography (eluting solvent: 30%
ethyl acetate-hexane) to obtain 480 mg (yield: 78%) of a
main product. 866 mg (yield: 58%) of the main product was
obtained from 1.43 mg (2.76 mmol) of the second fraction by
the same operation.
To 440 mg (1.82 mmol) of the product (obtained from the
first fraction) were added 3 ml of tetrahydrofuran and 4.1
ml of a solution of 1M tetrabutylammonium fluoride in
tetrahydrofuran, followed by heating under reflux for 4
hours.
After the reaction solution was cooled to room
temperature, an ammonium acetate aqueous solution and
chloroform were added to the solution to extract an organic
layer. The thus-obtained organic layer was washed with
saturated brine, and dried over anhydrous magnesium sulfate.
After the solvent was distilled off, the residue was
purified by silica gel column chromatography (eluting
solvent: 2% methanolchloroform) to obtain 220 mg of a main
product. 490 mg of main product was obtained from 760 mg
(1.4 mmol) of a main product obtained from the second
fraction by the same operation as the above. Both of the
thus obtained both main products were mixed, and 20 ml of
chloroform and 10 ml of 1N hydrochloric acid were added to
the mixture, followed by vigorous stirring at room
temperature for 2 hours. The organic layer was washed with
water and dried over anhydrous magnesium sulfate, and the
solvent was distilled off under reduced pressure to obtain
590 mg (total yield: 14%) of titled compound 16.
1H-NMR(CDCl3)δ(ppm); 11.31(br(s), 1H), 8.17(d, J=8.4Hz, 2H), 7.70(d,
J=14.8Hz, 1H), 7.66(d, J=7.9Hz, 2H), 6. 52(d, J=15.8Hz, 1H), 4.49-4.40(m,
2H), 4.33-4.25(m, 4H), 4.05-3.95(m, 1H), 1.94-1.76(m, 2H),
1.43(t, J=6.9Hz, 3H), 1.36(t, J=7.4Hz, 3H), 1.15(t, J=7.4Hz, 3H) MS(m/e); 407 (M+)
Example 17
(E)-4-(4,8-Diethyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]-purine-5-one-2yl)cinnamic
acid (Compound 17)
Example 15 was repeated except that 660 mg (1.62 mmol)
of compound 16 obtained in Example 16 was used to obtain 345
mg (yield: 56%) of titled compound 17 as yellow crystals.
1H-NMR(DHSO-d6)δ(ppm); 8.12(d, J=7.9Hz, 2H), 7.77(d, J=8.4Hz, 2H),
7.61(d, J=16.3Hz, 1H), 6.56(d, J=15.8Hz, 1H), 4.33-4.26(m, 2H), 4.16-4.07(m,
2H), 3.87-3.73(m, 1H), 1.78-1.63(m, 2H), 1.29(t, J=6.9Hz, 3H),
0.96(t, J=7.4Hz, 3H) MS(m/e); 379 (M+) IR(KBr, cm-1); 2940, 1715, 1675, 1580 Melting point; > 300°C
Elementary analysis ; For C20H21N5O3 1.1H2O, |
Found (%): | C 60.24, | H 5.72, | N 17.21 |
Calculated (%): | C 60.17, | H 5.86, | N 17.54 |
Example 18
Ethyl (E)-4-(4-propyl-1,4,7,8-tetrahydro-5H-imidazo
[2,1-i]purine-5-one-2-yl)cinnamate (Compound 18)
9.36 g (21 mmol) of compound 5 obtained in Example 5
was suspended in 80 ml of tetrahydrofuran, and 17.6 ml (126
mmol) of triethylamine and 11.2 ml (63 mmol) of 2-(chloromethoxy)ethyl
trimethylsilane were added to the
resultant suspension, followed by stirring at room
temperature overnight. To the reaction solution were added
ethyl acetate and water to extract an organic layer. The
thus-obtained organic layer was washed with saturated brine
and dried over anhydrous magnesium sulfate, and the solvent
was distilled off, followed by purification by silica gel
column chromatography (eluting solvent: 30% ethyl acetate-hexane
for the first fraction, 50% ethyl acetate-hexane for
the second fraction) to obtain 3.31 g (total yield of the
first and second fractions; 31%) of a main product.
900 mg (1.78 mmol) of the thus-obtained main product
(first fraction) was dissolved in 5 ml of dimethylformamide,
and 2.49 ml (17.85 mmol) of triethylamine, 1.90 ml (17.85
mmol) of ethyl acrylate and 60 mg (0.09 mmol) of
dichlorobistriphenylphosphine palladium were added to the
resultant solution, followed by stirring at 100°C for 5
hours. After the reaction solution was cooled to room
temperature, chloroform and water were added to the reaction
solution to extract an organic layer. The thus-obtained
organic layer was dried over anhydrous magnesium sulfate,
and the solvent was distilled off, followed by purification
by silica gel column chromatography (eluting solvent: 30%
ethyl acetate-hexane) to obtain 720 mg (yield: 78%) of a
main product.
To 690 mg (1.32 mmol) of the product (obtained from the
first fraction) were added 15 ml of ethanol and 15 ml of 1N
hydrochloric acid, followed by heating under reflux for 2
hours. After the reaction solution was cooled to room
temperature, the solution was neutralized with 2N sodium
hydroxide aqueous solution, and the precipitated crystals
were filtered off. The crystals obtained were washed with
water and then dried to obtain 480 mg (total yield: 22%) of
titled compound 18.
1H-NMR(DMSO-d6)δ(ppm); 8. 13(d, J=8.5Hz, 2H), 7. 93(d, J=8.6Hz, 2H),
7.70(d, J=16.2Hz, 1H), 6.76(d, J=16.2Hz, 1H), 4.25-4. 17(m, 4H), 4.11-4.01(m,
4H), 1.77(q, J=7.3Hz, 2H), 1.28(t, J=7.3Hz, 3H), 0.94(t,
J=7.3Hz, 3H) MS(m/e); 393 (M+)
Example 19
(E)-4-(4-Propyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]-purine-5-one-2-yl)cinnamic
acid (Compound 19)
Example 15 was repeated except that 450 mg (1.14 mmol)
of compound 18 obtained in Example 18 was used to obtain 110
mg (yield: 26%) of titled compound 19 as yellow crystals.
1H-NMR(DMSO-d6)δ(ppm); 8.12(d, J=8.2Hz, 2H), 7.71(d, J=8.2Hz, 2H),
7.60(d, J=15.8Hz, 1H), 6.52(d, J=15.8Hz, 1H), 4.15(t, J=7.9Hz, 2H),
4.03(t, J=6.6Hz, 2H), 3.90(t, J=9.9Hz, 2H), 1.77(q, J=7.6Hz, 2H),
0. 93(t, J=7.6Hz, 3H) MS(m/e); 366 (M+) IR(KBr, cm-1); 2960, 1705, 1580, 1422 Melting point; > 300°C
Elementary analysis; For C19H19N5O3 0.6H2O, |
Found (%): | C 60.56, | H 5.32, | N 18.48 |
Calculated (%): | C 60.66, | H 5.41, | N 18.62 |
Example 20
Ethyl (E)-4-(8-Ethyl-4-propyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one-2-yl)cinnamate
(Compound 20)
Example 14 was repeated except that 9.57 g (20.2 mmol)
of compound 8 obtained in Example 8 was used to obtain 1.91
g (yield: 23%) of titled compound 20.
1H-NMR(CDCl3)δ(ppm); 8.17(d, J=8.3Hz, 2H), 7.70(d, J=15.8Hz, 1H),
7.62(d, J=8.3Hz, 2H), 6.50(d, J=16.2Hz, 1H), 4.42-4.14(m, 6H), 3.95-3.88(m,
1H), 1.88(q, J=7.6Hz, 2H), 1.74-1.68(m, 2H), 1.35(t, J=7.3Hz,
3H), 1.03(t, J=7.3Hz, 3H), 0.97(t, J=7.3Hz, 3H) MS(m/e); 421 (M+)
Example 21
(E)-4-(8-Ethyl-4-propyl-1,4,7,8-tetrahydro-5H-imidazo-12,1-i]purine-5-one-2-yl)cinnamic
acid (Compound 21)
Example 15 was repeated except that 1.52 g (3.62 mmol)
of compound 20 obtained in Example 20 was used to obtain 720
mg (yield: 52%) of titled compound 21 as yellow crystals.
1H-NMR(DHSO-d6)δ(ppm); 8.12(d, J=8.2Hz, 2H), 7.70(d, J=8.3Hz, 2H),
7.60(d, J=15.8Hz, 1H), 6.51(d, J=16.2Hz, 1H), 4.30-4.14(m, 2H),
4.03(t, J=6.6Hz, 2H), 3.79(q, J=5.0Hz, 1H), 1.79(q, J=5.0Hz, 2H),
1.83-1.66(m, 2H), 0.99-0.88(m, 6H) MS(m/e); 392 (M+) IR(KBr, cm-1); 2960, 1715, 1580, 1375 Melting point; > 300°C
Elementary analysis; |
Found (%): | C 61.58, | H 5.84, | N 17.28 |
Calculated (%): | C 61.57, | H 6.10, | N 17.10 |
Example 22
2-(m-Bromophenyl)-4-propyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
hydrochloride (Compound 22)
Example 1 was repeated except that 2.0 g (5.29 mmol) of
compound
o obtained in Reference Example 13, 1.57 ml (26.5
mmol) of 2-aminoethanol, and 2.93 ml (40.2 mmol) of thionyl
chloride were used to obtain 1.53 g (yield: 78%) of titled
compound 22 as a white solid.
1H-NMR(DMSO-d6)δ(ppm); 10.45(s(br), 1H), 8.26(s(br), 1H), 8.11(d,
J=7.9Hz, 1H), 7.79(d, J=7.9Hz, 1H), 7.57(t, J=7.9Hz, 1H), 4.40-3.84(m,
6H), 1.77(q, J=7.4Hz, 2H), 0.95(t, J=7.4Hz, 3H) MS(m/e); 375, 373 (M+) IR(KBr, cm-1); 1706, 1687, 1656, 1565, 1274 Melting point; 290.5 - 292.0°C
Elementary analysis; For C16H16N5OBr 2.4HCl, |
Found (%): | C 41.58, | H 3.91, | N 14.83 |
Calculated (%): | C 41.62, | H 4.02, | N 15.17 |
Example 23
2-(m-Bromophenyl)-8-ethyl-4-propyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
hydrochloride (Compound 23)
Example 1 was repeated except that 1.5 g (3.97 mmol) of
compound
o obtained in Reference Example 13, 1.87 ml (19.9
mmol) of 2-aminobutanol, and 2.41 ml (33.0 mmol) of thionyl
chloride were used to obtain 1.2 g (yield: 65%) of titled
compound 23 as a yellow solid.
1H-NMR(DMSO-d6)δ(ppm); 10.24(s(br), 1H), 8.27(s(br), 1H), 8. 10(d,
J=7.9Hz, 1H), 7.79(d, J=7.9Hz, 1H), 7.57(t, J=7.9Hz, 1H), 4.41-3.75(m,
5H), 1.81-1.69(m, 4H), 1.13-0.92(m, 6H) MS(m/e); 403, 401 (M+) IR(KBr, cm-1); 1728, 1693, 1664, 1465 Melting point; 256.5 - 257.0°C
Elementary analysis; For C18H20N5OBr 1.7HCl, |
Calculated value (%): | C 46.81, | H 4.69, | N 14.78 |
Measured value (%): | C 46.57, | H 4.71, | N 15.08 |
Example 24
8-Ethyl-2-phenyl-4-propyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
(Compound 24)
Example 1 was repeated except that 1.2 g (4.0 mmol) of
compound
p obtained in Reference Example 14, 1.9 ml (20.0
mmol) of 2-aminobutanol, and 1.6 ml (21.8 mmol) of thionyl
chloride were used to obtain a hydrochloride of titled
compound 24. To the thus-obtained hydrochloride were added
chloroform and a 1N sodium hydroxide aqueous solution to
extract an organic layer. The organic layer was dried over
anhydrous magnesium sulfate, and the solvent was distilled
off under reduced pressure, followed by recrystallization
from ethanol to obtain 0.68 g (yield: 53%) of titled
compound 24 as a white solid.
1H-NMR(DHSO-d6)δ(ppm); 10.40(s(br), 1H), 8.13-8.11(m, 2H), 7.61-7.54(m,
3H), 4.55-3.75(m, 5H), 1.79-1.73(m, 4H), 1.06-0.89(m, 6H) MS(m/e); 323 (M+) IR(KBr, cm-1); 1704, 1687, 1683, 1558 Melting point; 262.8 - 263.5°C
Elementary analysis; For C18H20N5O 0.4H2O, |
Found (%): | C 65.49, | H 6.55, | N 21.26 |
Calculated (%): | C 65.60, | H 6.36, | N 21.25 |
Example 25
2-(p-Bromophenyl)-8-ethyl-4-methyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
hydrochloride (Compound 25)
Example 1 was repeated except that 1.3 g (3.71 mmol) of
compound
g obtained in Reference Example 15, 1.75 ml (18.6
mmol) of 2-aminobutanol, and 4.0 ml (54.5 mmol) of thionyl
chloride were used to obtain 0.56 g (yield: 34%) of titled
compound 25 as a pale brown solid.
1H-NMR(DMSO-d6)δ(ppm); 8.02(d, J=8.4Hz, 2H), 7.81(d, J=8.4Hz, 2H),
4.43-4.29(m, 2H), 3.94-3.85(m, 1H), 3.51(s, 3H), 1.79-1.69(m, 2H),
0.98(t, J=6.9Hz, 3H) MS(m/e); 375, 373 (M+) IR(KBr, cm-1); 1716, 1704, 1700, 1596 IR (KBr, cm-1); 1716, 1704, 1700, 1596 Melting point; > 295°C
Elementary analysis; For C16H16N5OBr 1.4H2O1.8HCl, |
Found (%): | C 41.43, | H 4.47, | N 14.86 |
Calculated (%): | C 41.32, | H 4.46, | N 15.06 |
Example 26
2-(p-Bromophenyl)-4-n-butyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
hydrochloride (Compound 26)
Example 1 was repeated except that 2.0 g (5.13 mmol) of
compound
r obtained in Reference Example 16, 1.52 ml (25.6
mmol) of 2-aminoethanol, and 1.62 ml (22.2 mmol) of thionyl
chloride were used to obtain 1.29 g (yield: 63%) of titled
compound 26 as a white solid.
1H-NMR(DMSO-d6)δ(ppm); 9.97(s(br), 1H), 8.02(d, J=8.9Hz, 2H), 7.58(d,
J=8.9Hz, 2H), 4.17-3.85(m, 6H), 1.77-1.66(m, 1H), 1.41-1.27(m, 2H),
0.93(t, J=7.4Hz, 3H) MS(m/e); 389, 387(M+) IR(KBr, cm-1); 1679, 1670, 1602, 1469, 1411 Melting point; > 300°C
Elementary analysis; For C17H18N5OBr 2.0HCl, |
Found (%): | C 44.55, | H 4.43, | N 14.93 |
Calculated (%): | C 44.27, | H 4.37, | N 15.19 |
Example 27
2-(p-Bromophenyl)-4-n-butyl-8-ethyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
(Compound 27)
Example 1 was repeated except that 2.0 g (5.13 mmol) of
compound
r obtained in Reference Example 16, 2.04 ml (25.6
mmol) of 2-aminobutanol, and 1.62 ml (22.2 mmol) of thionyl
chloride were used to obtain 1.76 g (yeild: 71%) of
hydrochloride of titled compound 27. To the thus-obtained
hydrochloride were added chloroform and a 1N sodium
hydroxide aqueous solution to extract an organic layer.
The organic layer was dried over anhydrous magnesium sulfate,
and the solvent was distilled off under reduced pressure,
followed by recrystallization from ethanol to obtain 0.89 g
(yield: 41%) of titled compound 27 as a brown solid.
1H-NMR(DMSO-d6)δ(ppm); 10.34(s(br), 1H), 8.02(d, J=8.4Hz, 2H), 7.60(d,
J=8.4Hz, 2H), 4.30-4.15(m, 2H), 4.06(t, J=6.9Hz, 2H), 3.82-3.72(m,
1H), 1.77-1.63(m, 4H), 1.41-1.27(m, 2H), 0.98-0.90(m, 6H) MS(m/e); 417, 415(M+) IR(KBr, cm-1); 1704, 1691, 1664, 1544, 1263 Melting point; 268.7 - 269. 7°C
Elementary analysis; For C19H22N5OBr 0.4H2O, |
Found (%): | C 54.00, | H 5.38, | N 16.17 |
Calculated (%): | C 53.88, | H 5.43, | N 16.54 |
Example 28
2-(p-Bromophenyl)-8-ethyl-4-phenyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
hydrochloride (Compound 28)
Example 1 was repeated except that 2.0 g (4.85 mmol) of
compound
s obtained in Reference Example 17, 2.3 ml (24.3
mmol) of 2-aminobutanol, and 1.62 ml (22.2 mmol) of thionyl
chloride were used to obtain 1.0 g (yield: 41%) of titled
compound 28 as a white solid.
1H-NMR(DMSO-d6)δ(ppm); 7.89-7.75(m, 4H), 7.60-7.54(m, 5H), 4.35-3.50(m,
3H), 1.85-1.63(m, 2H), 1.01-0.95(m, 3H) MS(m/e); 435(M+) IR(KBr, cm-1); 1716, 1670, 1587 Melting point; > 300°C
Elementary analysis; For C21H18N5OBr 1.9HCl, |
Found (%): | C 50.06, | H 4.18, | N 13.85 |
Calculated (%): | C 49.89, | H 3.97, | N 13.85 |
Example 29
2-(p-Bromophenyl)-4-(3-iodobenzyl)-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
hydrochloride (Compound 29)
Example 1 was repeated except that 0.6 g (1.08 mmol) of
compound
t obtained in Reference Example 18, 0.32 ml (5.42
mmol) of 2-aminoethanol, and 0.33 ml (4.5 mmol) of thionyl
chloride were used to obtain 0.22 g (yield: 33%) of titled
compound 29 as a brown solid.
1H-NMR(DMSO-d6)δ(ppm); 10.19(s(br), 1H), 8.03-7.65(m, 5H), 7.43(d,
J=7.3Hz, 1H), 7.16(t, J=7.3Hz, 1H), 5.23(s, 2H), 4.27-3.72(m, 4H) MS(m/e); 549, 547(M+) IR(KBr, cm-1); 1716, 1673, 1602, 1471 Melting point; > 263.5 - 266.2°C
Example 30
2-(p-Bromophenyl)-8-ethyl-4-(3-iodobenzyl)-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
hydrochloride
(Compound 30)
Example 1 was repeated except that 0.4 g (0.72 mmol) of
compound
t obtained in Reference Example 18, 0.29 ml (3.61
mmol) of 2-aminobutanol, and 0.23 ml (3.1 mmol) of thionyl
chloride were used to obtain 0.11 g (yield: 24%) of titled
compound 30 as a brown solid.
1H-NMR(DMSO-d6)δ(ppm); 8.03-7.12(m, 8H), 5.25(s, 2H), 4.47-4.31(m,
2H), 3.98-3.87(m, 1H), 1.81-1.70(m, 2H), 0. 98(t, J=7.9Hz, 3H) MS(m/e); 577(M+) IR(KBr, cm-1); 1716, 1700, 1683, 1587 Melting point; 217.5 - 219.5°C
Elementary analysis; For C22H19N5OIBr 1.7HCl, |
Found (%): | C 41.54, | H 3.46, | N 10.63 |
Calculated (%): | C 41.40, | H 3.27, | N 10.97 |
Example 31
2-(p-Bromophenyl)-4-(3-iodobenzyl)-1,4,5,7,8,9-hexahydropyrimido[2,1-i]purine-5-one
(Compound 31)
Example 1 was repeated except that 0.4 g (0.72 mmol) of
compound
t obtained in Reference Example 18, 0.29 ml (3.61
mmol) of 2-aminobutanol, and 0.23 ml (3.1 mmol) of thionyl
chloride were used to obtain a hydrochloride of titled
compound 31. To the thus-obtained hydrochloride were added
chloroform and a 1N sodium hydroxide aqueous solution to
extract an organic layer. The organic layer was dried over
anhydrous magnesium sulfate, and the solvent was distilled
off under reduced pressure, followed by recrystallization
from ethanol to obtain 0.15 g (yield: 35%) of titled
compound 31 as a pale brown solid.
1H-NMR(CDCl3)δ(ppm); 8.08(d, J=8.4Hz, 2H), 8.00(s, 1H), 7.64-7.59(m,
1H), 7.54(d, J=8.4Hz, 2H), 7.06(t, J=7.4Hz, 1H), 5.32(s, 2H), 4.03(t,
J=5.9Hz, 2H), 3.22(t, J=5.4Hz, 2H), 1.09-2.00(m, 2H) MS(m/e); 561(M+) IR(KBr, cm-1); 1716, 1683, 1651, 1558 Melting point; 287.5 - 290.0°C
Elementary analysis; For C21H17N5OIBr 0.4C2H5OH 0.8H2O, |
Found (%): | C 44.00, | H 3.26, | N 11.50 |
Calculated (%): | C 44.00, | H 3.55, | N 11.77 |
Example 32
(R)-2-(p-Bromophenyl)-8-isopropyl-4-propyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
(Compound 32)
Example 1 was repeated except that 2.0 g (5.29 mmol) of
compound
f obtained in Reference Example 6, 2.92 ml (26.45
mmol) of (R)-(-)-2-amino-3-methyl-1-butanol, and 3.11 ml
(42.6 mmol) of thionyl chloride were used to obtain a
hydrochloride of titled compound 32. To the thus-obtained
hydrochloride were added chloroform and a 1N sodium
hydroxide aqueous solution to extract an organic layer.
The organic layer was dried over anhydrous magnesium sulfate,
and the solvent was distilled off under reduced pressure,
followed by recrystallization from ethanol to obtain 0.72 g
(yield: 33%) of titled compound 32 as a white solid.
1H-NMR(DMSO-d6)δ(ppm); 8.03(d, J=8.4Hz, 2H), 7.60(d, J=8.4Hz, 2H),
4.25-3.99(m, 4H), 3.88-3.82(m, 1H), 1.93-1.85(m, 1H), 1.76(q, J=7.4Hz,
2H), 0.97-0.87(m, 9H) MS(m/e); 417, 415(M+) IR(KBr, cm-1); 1700, 1687, 1546, 1265 Melting point; 156.5 - 157.5°C
Elementary analysis; For C19H22N5OBr 0.5C2H5OH 0.5H2O, |
Found (%): | C 53.67, | H 5.86, | N 15.58 |
Calculated (%): | C 53.58, | H 5.84, | N 15.62 |
Example 33
(S)-2-(p-Bromophenyl)-8-isopropyl-4-propyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
(Compound 33)
Example 1 was repeated except that 2.0 g (5.29 mmol) of
compound
f obtained in Reference Example 6, 2.73 g (26.45
mmol) of (S)-(+)-2-amino-3-methyl-1-butanol, and 1.51 ml
(20.75 mmol) of thionyl chloride were used to obtain a
hydrochloride of titled compound 33. To the thus-obtained
hydrochloride were added chloroform and a 1N sodium
hydroxide aqueous solution to extract an organic layer.
The organic layer was dried over anhydrous magnesium sulfate,
and the solvent was distilled off under reduced pressure,
followed by recrystallization from ethanol to obtain 1.08 g
(yield: 49%) of titled compound 33 as a white solid.
1H-NMR(DMSO-d6)δ(ppm); 10.20(s(br), 1H), 8.03(d, J=8.4Hz, 2H), 7.60(d,
J=8.4Hz, 2H), 4.25-3.99(m, 4H), 3.88-3.82(m, 1H), 1.95-1.69(m, 3H),
0.99-0.89(m, 9H) MS(m/e); 417, 415(M+) IR(KBr, cm-1); 1706, 1664, 1542, 1265 Melting point; 279.3 - 279.7°C
Elementary analysis; For C19H22N5OBr 0.7C2H5OH 0.6H2O, |
Found (%): | C 53.45, | H 5.91, | N 15.16 |
Calculated (%): | C 53.34, | H 6.01, | N 15.26 |
Example 34
(S)-2-(p-Bromophenyl)-8-phenyl-4-propyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
(Compound 34)
Example 1 was repeated except that 0.2 g (0.53 mmol) of
compound
f obtained in Reference Example 6, 290 mg (2.11
mmol) of (S)-(+)-phenylglycinol, and 0.15 ml (21.2 mmol) of
thionyl chloride were used to obtain a hydrochloride of
titled compound 34. To the thus-obtained hydrochloride were
added chloroform and a 1N sodium hydroxide aqueous solution
to extract an organic layer. The organic layer was dried
over anhydrous magnesium sulfate, and the solvent was
distilled off under reduced pressure, followed by
recrystallization from ethanol to obtain 0.10 g (yield: 42%)
of titled compound 34 as a white solid.
1H-NMR(DMSO-d6)δ(ppm); 8.08-7.81(m, 4H), 7.57-7.41(m, 5H), 5.66-5.59(m,
1H), 4.75(t, J=10.9Hz, 1H), 4.12-3.98(m, 3H), 1.79(q, J=7.4Hz,
2H), 0.97(t, J=7.4Hz, 3H) MS(m/e); 451, 449(M+) IR(KBr, cm-1); 1697, 1670, 1546, 1263 Melting point; 168.5 - 170.3°C
Elementary analysis; For C22H20N5OBr 0.5C2H5OH 1.2H2O, |
Found (%): | C 55.81, | H 4.84, | N 14.03 |
Calculated (%): | C 55.81, | H 5.17, | N 14.15 |
Example 35
(R)-2-(p-Bromophenyl)-8-phenyl-4-propyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
(Compound 35)
Example 1 was repeated except that 0.2 g (0.53 mmol) of
compound
f obtained in Reference Example 6, 290 mg (2.11
mmol) of (R)-(-)-phenylglycinol, and 0.15 ml (21.2 mmol) of
thionyl chloride were used to obtain a hydrochloride of
titled compound 35. To the thus-obtained hydrochloride
were added chloroform and a 1N sodium hydroxide aqueous
solution to extract an organic layer. The organic layer
was dried over anhydrous magnesium sulfate, and the solvent
was distilled off under reduced pressure, followed by
recrystallization from ethanol to obtain 0.08 g (yield: 34%)
of titled compound 35 as a white solid.
1N-NMR(DMSO-d6)δ(ppm); 8.10-7.81(m, 4H), 7.58-7.39(m, 5H), 5.67-5.60(m,
1H), 4.76(t, J=10.9Hz, 1H), 4. 13-3.98(m, 3H), 1.79(q, J=7.4Hz,
2H), 0.97(t, J=7.4Hz, 3H) MS(m/e); 451, 449(M+) IR(KBr, cm-1); 1697, 1670, 1651, 1540 Melting point; 168.8 - 170.2°C
Elementary analysis; For C22H20N5OBr 0.5C2H5OH 0.7H2O, |
Found (%): | C 56.92, | H 4.99, | N 14.34 |
Calculated (%): | C 56.84, | H 5.06, | N 14.41 |
Example 36
8-Ethyl-2-(3-iodophenyl)-4-propyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
hydrochloride (Compound 36)
Example 1 was repeated except that 0.3 g (0.70 mmol) of
compound
u obtained in Reference Example 19, 0.28 ml (3.52
mmol) of 2-aminobutanol, and 0.47 ml (6.67 mmol) of thionyl
chloride were used to obtain 0.25 g (yield: 74%) of titled
compound 36 as a solid.
1H-NMR(DMSO-d6)δ(ppm); 8.44(s(br), 1H), 8.12(d(br), J=7.6Hz, 1H),
95(d, J=7.6Hz, 2H), 7.41(t, J=7.6Hz, 1H), 7.41(t, J=7.9Hz, 1H), 4.05-3.72(m,
5H), 1.80-1.71(m, 4H), 1.01-0.91(m, 6H) MS(m/e); 449(M+) IR(KBr, cm-1); 1741, 1712, 1646, 1558 Melting point; 218.0 - 220.0°C
Elementary analysis; For C18H20N5OI 0.7HCl 0.6H2O, |
Found (%): | C 44.55, | H 4.50, | N 14.11 |
Calculated (%): | C 44.52, | H 4.55, | N 14.42 |
Example 37
2-(2-Furyl)-4-propyl-1,4,7,8-tetrahydro-5H-imidazo-[2,1-i]purine-5-one
hydrochloride (Compound 37)
Example 1 was repeated except that 300 mg (1.04 mmol)
of compound
v obtained in Reference Example 20, 0.44 ml
(7.27 mmol) of 2-aminoethanol, and 1 ml (13.71 mmol) of
thionyl chloride were used to obtain 159 mg (yield: 54%) of
titled compound 37 as a solid.
MS(m/e); 285(M+) IR(KBr, cm-1); 1716, 1677, 1511 Melting point; 235.5 - 238.0°C
Example 38
8-Ethyl-2-(2-furyl)-4-propyl-1,4,7,8-tetrahydro-5H-imidazo[2,1-i]purine-5-one
hydrochloride (Compound 38)
Example 1 was repeated except that 300 mg (1.04 mmol)
of compound
v obtained in Reference Example 20, 0.69 ml
(7.27 mmol) of 2-aminobutanol, and 1 ml (13.71 mmol) of
thionyl chloride were used to obtain 40 mg (yield: 12%) of
titled compound 38 as a solid.
MS(m/e); 313(M+) IR(KBr, cm-1); 1712, 1677, 1511 Melting point; 205.0 - 206.5°C
Reference Example 1
8-(p-Bromophenyl)-3-ethylxanthine (compound a)
5.70 g (28.53 mmol) of p-bromobenzoic acid was
suspended in a solvent mixture of 100 ml of
dimethylformamide and 100 ml of dichloromethane, and 4.90 g
(32.60 mmol) of 1-hydroxybenzotriazole and 7.80 g (40.76
mmol) of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
hydrochloride were added in turn to the resultant suspension,
followed by stirring at room temperature for 5 minutes.
Next, to the suspension was added 5.0 g (27.17 mmol) of 5,6-diamino-1-ethyl-2(1H,3H)-pyrimidinedione
(Japanese
Unexamined Patent Publication No. 80-57517), followed by
stirring at room temperature overnight. After
dichloromethane was distilled off under reduced pressure,
the residue was poured into 600 ml of water. The insoluble
substance was filtered off, dried under reduced pressure,
and then suspended in a solvent mixture of 100 ml of 4N
sodium hydroxide aqueous solution and 100 ml of ethanol,
followed by heating under reflux for 2 hours. The reaction
solution was cooled to room temperature, and then
neutralized with conc. hydrochloric acid. Then the
crystals obtained were collected off, and dried under
reduced pressure to obtain 6.78 g (yield: 79%) of titled
compound
a.
1H-NMR(DMSO-d6)δ(ppm); 13.91(s(br) 1H), 12.08(s(br), 1H), 8.06(d,
J=7.9Hz, 2H), 7.73(d, J=7.9Hz, 2H), 4.10-3.95(m, 2H), 1.35-1.20(m,
3H) MS(m/e); 336, 334 (M+)
Reference Example 2
8-(p-Bromophenyl)-3-ethyl-6-thioxanthine (compound b)
2.5 g (7.48 mmol) of compound
a obtained in Reference
Example 1 was heated in 50 ml of pyridine together with 2.66
g (11.9 mmol) of phosphorus pentasulfide and 1.66 ml (11.9
mmol) of triethylamine under reflux for 4 hours. The
reaction solution was poured into 200 ml of ice-water, and
the precipitated crystals were collected off, and washed
well with water and then ether. The thus-obtained crystals
were dried under reduced pressure to obtain 2.22 g (yield:
85%) of titled compound
b.
1H-NMR(DMSO-d6)δ(ppm); 13.86(s(br), 1H), 12.23(s(br), 1H), 8.18(d,
J=8.6Hz, 2H), 7.73(d, J=8.6Hz, 2H), 4.05(q, J=6.9Hz, 2H), 1.28(t,
J=6.9Hz, 3H)) MS(m/e); 352, 350 (M+)
Reference Example 3
8-(p-Bromophenyl)-3-ethyl-6-methylthio-3-dihydro-2H-purine-2-one
(compound c)
10 g (28.57 mmol) of compound
b obtained in Reference
Example 2 was dissolved in a solvent mixture of 100 ml of
ethanol and 100 ml of 2N sodium hydroxide aqueous solution,
and 2.67 ml (42.8 mmol) of iodomethane was slowly added to
the resultant solution under ice cooling, followed by
stirring at room temperature for 1 hour. The solution was
neutralized with conc. hydrochloric acid, and the obtained
crystals were collected and dried under reduced pressure to
obtain 10.8 g (yield: quantitative) of titled compound
c.
1H-NMR(DMSO-d6)δ(ppm); 13.69(s(br), 1H), 8.11(d, J=8.4Hz, 2H), 7. 77(d,
J=8.4Hz, 2H), 4.14(q, J=6.9Hz, 2H), 3.31(s, 3H), 1.27(t, J=6.9Hz, 3H) MS(m/e); 364 (M+)
Reference Example 4
8-(p-Bromophenyl)-3-propylxanthine (compound d)
Reference Example 1 was repeated except that 45 g (240
mmol) of 5,6-diamino-1-propyl-2(1H,3H)-pyrimidinedione
(Japanese Unexamined Patent Publication No. 80-57517) was
used in place of 5,6-diamino-1-ethyl-2-(1H,3H)-pyrimidinedione
to obtain 63.7 g (yield: 74%) of titled
compound
d as a white powder.
1H-NMR(DMSO-d6)δ(ppm); 13.86(s(br), 1H), 12.23(s(br), 1H), 8.18(d,
J=8.5Hz, 2H), 7.73(d, J=8.5Hz, 2H), 3.95(q, J=7.3Hz, 3H), 1.73(q,
J=7.3Hz, 2H), 0.91(t, J=7.3Hz, 3H) MS(m/e); 350, 348 (M+)
Reference Example 5
8-(p-Bromophenyl)-3-propyl-6-thioxanthine (compound e)
Reference Example 2 was repeated except that 50 g (144
mmol) of compound
d obtained in Reference Example 4 was used
to obtain 44.9 g (yield: 86%) of titled compound
e.
1H-NMR(DMSO-d6)δ(ppm); 13.84(s, 1H), 12.30(s, 1H), 8.18(d, J=8.9Hz,
2H), 7.74(d, J=8.9Hz, 2H), 3.98(t, J=7.3Hz, 2H), 1.79-1.70(m, 2H),
0.92(t, J=7.3Hz, 3H) MS(m/e); 366, 364 (M+)
Reference Example 6
8-[p-Bromophenyl)-6-methylthio-3-propyl-3-dihydro-2H-purine-2-one
(compound f)
Reference Example 3 was repeated except that 20 g (55.0
mmol) of compound
e obtained in Reference Example 5 was used
to obtain 21.0 g (yield: quantitative) of titled compound
f.
1H-NMR(DMSO-d6)δ(ppm); 8.11(d, J=8.4Hz, 2H), 7.77(d, J=8.4Hz, 2H),
4. 05(t, J=7.4Hz, 2H), 2.63(s, 3H), 1.72(q, J=7.4Hz, 2H), 0. 91(t,
J=7.4Hz, 3H) MS(m/e); 380, 378 (M+)
Reference Example 7
8-(o-Bromophenyl)-3-propylxanthine (compound g)
Reference Example 1 was repeated except that 20.0 g
(117.6 mmol) of 5,6-diamino-1-propyl-2(1H,3H)-pyrimidineone
(Japanese Unexamined Publication No. 80-57517) and 22.9 g
(114 mmol) of o-bromobenzoic acid were used to obtain 17.8 g
(yield: 39%) of titled compound
g.
1H-NMR(DMSO-d6)δ(ppm); 11.13(s, 1H), 7.9(d, J=7.9Hz, 1H), 7.65(d,
J=7.4Hz, 1H), 7.65(dd, J=7.4Hz, 2.0Hz, 1H), 7.55-7.42(m, 2H), 3.93(t,
J=7.4Hz, 2H), 1.72(q, J=7.4Hz, 2H), 0.89(t, J=7.4Hz, 3H) MS(m/e); 350, 348 (M+)
Reference Example 8
8-(o-Bromophenyl)-3-propyl-6-thioxanthine (compound h)
Reference Example 2 was repeated except that 10 g (48.5
mmol) of compound g obtained in Reference Example 7 was used
to obtain 26.8 g (yield: quantitative) of titled compound
h.
1H-NMR(DMSO-d6)δ(ppm); 13.78(s, 1H), 12.35(s, 1H), 7.80(d, J=7.4Hz,
1H), 7.67(dd, J=7.4Hz, 2.0Hz, 1H), 7.56-7.45(m, 2H), 3.96(t, J=6.4Hz,
2H), 1.72(q, J=7.4Hz, 2H), 0. 90(t, J=7.4Hz, 3H) MS(m/e); 366, 364 (M+)
Reference Example 9
8-(o-Bromophenyl)-6-methylthio-3-propyl-3-dihydro-2H-purine-2-one
(compound i)
Reference Example 3 was repeated except that 8.19 g
(22.5 mmol) of compound
h obtained in Reference Example 8
was used to obtain 7.32 g (yield: 86%) of titled compound
i.
1H-NMR(DMSO-d6)δ(ppm); 13.76(s, 1H), 7.83(d, J=7.9Hz, 1H), 7.70(d,
J=6.9Hz, 1H), 7.59-7.47(1, 2H), 4.09-3.98(m, 2H), 2.52(s, 3H), 1.73(q,
J=7.4Hz, 2H), 0.90(t, J=7.4Hz, 3H) MS(m/e); 380, 378 (M+)
Reference Example 10
3-Propyl-8-(p-tolyl)xanthine (compound j)
Reference Example 1 was repeated except that 6.0 g
(32.6 mmol) of 5,6-diamino-1-propyl-2(1H,3H)-pyrimidinedione
(Japanese Unexamined Patent Publication No. 80-57517) and
4.66 g (34.2 mmol) of p-methylbenzoic acid were used to
obtain 4.41 g (yield: 48%) of titled compound
j.
1H-NMR(DMSO-d6)δ(ppm); 13.70(s, 1H), 11.09(s, 1H), 7.99(d, J=8.4Hz,
2H), 7.31(d, J=8.4Hz, 2H), 3.95(t, J=6.9Hz, 2H), 2.36(s, 3H), 1.73(q,
J=7.4Hz, 2H), 0.91(t, J=7.4Hz, 3H) MS(m/e); 284 (M+)
Reference Example 11
3-Propyl-8-(ptolyl)-6-thioxanthine (compound k)
Reference Example 2 was repeated except that 4.0 g
(14.1 mmol) of compound
j obtained in Reference Example 10
was used to obtain 3.56 g (yield: 84%) of titled compound
k.
1H-NMR(DMSO-d6)δ(ppm); 13.64(s, 1H), 12.22(s, 1H), 8.14(d, J=7.9Hz,
2H), 7.34(d, J=8.4Hz, 2H), 3.98(t, J=7.4Hz, 2H), 2.37(s, 3H), 1.75(q,
J=7.9Hz, 2H), 0.92(t, J=7.4Hz, 3H) MS(m/e); 300 (M+)
Reference Example 12
6-Methylthio-3-propyl-8-(p-tolyl)-3-dihydro-2H-purine-2-one
(compound m)
Reference Example 3 was repeated except that 3.0 g
(10.0 mmol) of compound
k obtained in Reference Example 11
was used to obtain 3.1 g (yield: 97%) of titled compound
m.
1H-NMR(DMSO-d6)δ(ppm); 8.08(d, J=8.4Hz, 2H), 7.37(d, J=8.4Hz, 2H),
4.06(t, J=6.9Hz, 2H), 2.62(s, 3H), 2.39(s 3H), 1.74(q, J=7.4Hz, 2H),
0.91(t, J=7.4Hz, 3H) MS(m/e); 314 (M+)
The following compounds were synthesized in the same
manner as Reference Examples 1 to 3 using corresponding aryl
carboxylic acids and pyrimidine derivatives (Japanese
Unexamined Patent Publication No. 80-57517)
Reference Example 13
6-Methylthio-3-propyl-8-(m-bromophenyl)-3-dihydro-2H-purine-2-one
(compound o)
Yield: 54%
1H-NMR(DMSO-d6)δ(ppm); 8.38(s, 1H), 8.18(d, J=7.9Hz, 1H), 7.73(d,
J=7.9Hz, 1H), 7.52(t, J=7.9Hz, 1H), 4.06(t, J=7.4Hz, 2H), 2.64(s, 3H),
1.74(q, J=7.4Hz, 2H), 0.92(t, J=7.4Hz, 3H)
MS(m/e); 380, 378 (M+)
Reference Example 14
6-Methylthio-3-propyl-8-phenyl-3-dihydro-2H-purine-2-one
(compound p)
Yield: 27%
1H-NMR(DMSO-d6)δ(ppm); 8.22-8.17(m, 2H), 7.60-7.49(m, 3H), 4. 08(t,
J=7.4Hz, 2H), 2.65(s, 3H), 1.75(q, J=7.4Hz, 2H), 0.92(t, J=7.4Hz, 3H)
MS(m/e); 300 (M+)
Reference Example 15
6-Methylthio-3-methyl-8-(p-bromophenyl)-3-dihydro-2H-purine-2-one
(compound q)
Yield: 56%
1H-NMR(DMSO-d6)δ(ppm);8.11(d,J=8.4Hz,2H), 7.78(d, J=8.4Hz, 2H),
3.54(s, 3H), 2.66(s, 3H)
MS(m/e); 350 (M+)
Reference Example 16
6-Methylthio-3-n-butyl-8-(p-bromophenyl)-3-dihydro-2H-purine-2-one
(compound r)
Yield: 74
1H-NMR(DMSO-d6)δ(ppm); 8.14(d, J=8.9Hz, 2H), 7.77(d, J=8.9Hz, 2H),
4.10(t, J=7.4Hz, 2H), 2.64(s, 3H), 1.71(q, J=7.4Hz, 2H), 1.32(q,
J=7.4Hz, 2H), 0.93(t, J=7.4Hz, 3H)
MS(m/e); 392 (M+)
Reference Example 17
6-Methylthio-3-phenyl-8-(p-bromophenyl)-3-dihydro-2H-purine-2-one
(compound s)
Yield: 68%
1H-NMR(DMSO-d6)δ(ppm); 8.01(d, J=8.4Hz, 2H), 7.70(d, J=8.4Hz, 2H),
7.58-7.43(m, 5H), 2.67(s, 3H)
MS(m/e); 412(M+)
Reference Example 18
6-Methylthio-3-(3-iodobenzyl)-8-(p-bromophenyl)-3-dihydro-2H-purine-2-one
(compound t)
Yield: 81%
1H-NMR(DMSO-d6)δ(ppm); 8.54(s, 1H), 8.18(d, J=7.6Hz, 1H), 7.90(d,
J=7.6Hz, 1H), 7.36(t, J=7.9Hz, 1H), 4.05(t, J=7.3Hz, 2H), 2.61(s, 3H),
1.73(q, J=7.3Hz, 2H), 0. 91(t, J=7.6Hz, 3H)
MS(m/e); 551 (M+)
Reference Example 19
6-Methylthio-3-propyl-8-(m-iodophenyl)-3-dihydro-2H-purine-2-one
(compound u)
Yield: 64%
1H-NMR(DMSO-d6)δ(ppm); 13.71(s(br), 1H), 8.54(s, 1H), 8. 18(d, J=7.6Hz,
1H), 7.89(d, J=7.6Hz, 1H), 7. 36(t, J=7.6Hz, 1H), 4. 05(t, J=7.3Hz, 2H),
2.61(s, 3H), 1.74(q, J=7.3Hz, 2H), 0. 91(t, J=7.3Hz, 3H)
MS(m/e); 426 (M+)
Reference Example 20
6-Methylthio-3-propyl-8-(2-furyl)-3-dihydro-2H-purine-2-one
(compound v)
Yield: 87%
1H-NMR(DMSO-d6)δ(ppm); 13.80(s(br), 1H), 7. 97(5, 1H), 7.30(s, 1H),
6.75-6.74(m, 1H), 4.01(t, J=7.4Hz, 2H), 2.60(s, 3H), 1.71(q, J=7.4Hz,
2H), 0. 90(t, J=7.4Hz, 3H)
MS(m/e); 290 (M+)
Formulation Example 1
Tablet:
A tablet comprising the following composition is
prepared by a normal method.
Compound 1 | 10 mg |
Lactose | 30 mg |
Potato starch | 15 mg |
Polyvinyl alcohol | 1.5 mg |
Magnesium stearate | 0.5 mg |
Formulation Example 2
Capsule:
A capsule comprising the following composition is
prepared by a normal method.
Compound 1 | 10 mg |
Lactose | 100 mg |
Magnesium stearate | 2.5 mg |
These ingredients are mixed and filled in a gelatin
capsule.
Formulation Example 3
Injection:
An injection comprising the following composition is
prepared by a normal method.
Compound 1 | 2 mg |
Purified soybean oil | 200 mg |
Purified yolk lecithin | 24 mg |
Injection glycerin | 50 mg |
Injection distilled water | 1.72 ml |
Industrial Applicability
The present invention can provide condensed purine
derivatives exhibiting adenosine A3 antagonising activity,
and having an antiasthmatic action, a bronchodilator action,
an antiitching action, etc. Compounds (I) according the
present invention are useful for treating or preventing
diseases such as asthma, allergic rhinitis, hypersensitivity
angiitis, atopic dermatitis, psoriasis, urticaria, etc.